drugset / Trial / NCT04039347
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
Timeline
- Start
- 2020-03-12
- Primary completion
- 2026-02-25
- Completion
- 2026-02-25
Outcome
Outcome not reported
Stopped (Business): “Study was terminated for business reasons. The earlier study end is not related to any safety concerns or data issues identified at any site or within the overall study data collected to date.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 5 mg | Inhaled |
| Subject | Cyclosporine | Peptide | 10 mg | Inhaled |